MedTrace Logo

RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia

NCT07596485 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-19

No results posted yet for this study

Summary

The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.

Conditions

  • Trigeminal Neuralgia

Interventions

GENETIC

RP-008

RP-008 will be administered as a single percutaneous injection to the trigeminal ganglion.

DRUG

Varenicline tartrate

Varenicline tartrate will be administered as a daily oral tablet.

Sponsors & Collaborators

  • Kriya Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07596485 on ClinicalTrials.gov